All manuscripts
Publications CAR T Cells

Promises and challenges of a decentralized CAR T-cell manufacturing model

Published Journal Frontiers in Transplantation

Share
9 pages Promises and challenges of a decentralized CAR T-cell manufacturing model

Overview

This review makes the case for manufacturing autologous CAR T cells inside the hospital rather than at a central plant. It puts the cost at as little as 35,000 USD per patient when a sponsor supplies the vector, against nearly 500,000 USD for a commercial product, and turnaround at 7-10 days instead of 14.

What this paper found

Point-of-care manufacturing of autologous CAR T cells within academic healthcare systems is presented as a way to widen patient access and cut costs relative to the centralized commercial model, provided quality can be standardized. Commercial products total nearly $500,000 and patients may wait up to 3 weeks for a manufacturing slot. Decentralized production can shorten manufacturing to 7-10 days instead of 14 and may cost as little as $35,000 when a sponsor supplies the vector. Closed automated platforms such as CliniMACS Prodigy and Cocoon support this model. Main hurdles are GMP vector supply, trained staff, quality control, facilities and financing.

Note: This is a narrative review; the authors note that there are no commercially available point-of-care CAR T products in the USA and that comparability across sites must still be shown.

Quality control is one of the greatest challenges to implementing POC manufacturing as opposed to centralized manufacturing. — Manan Shah, Ashley Krull, Lynn Odonnell, Marcos J. de Lima, Evandro Bezerra, Frontiers in Transplantation

Study details

Authors
Manan Shah, Ashley Krull, Lynn Odonnell, Marcos J. de Lima, Evandro Bezerra
Institution
Department of Hematology, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States · Department of Cell Therapy Manufacturing and Engineering, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States · Department of Hematology, Cellular Therapy Lab, the James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, OH, United States
Journal
Frontiers in Transplantation
Year
2023
PMID / PMC
PMID: 38993860 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy

Explore related

Full citation

Shah M, Krull A, Odonnell L, de Lima MJ, Bezerra E. Promises and challenges of a decentralized CAR T-cell manufacturing model. Front Transplant. 2023;2:1238535.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →